In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovent Biologics Inc.

www.innoventbio.com/en/

Latest From Innovent Biologics Inc.

Changes Encourage Celltrion And Nan Fung To Bet On China Biosimilars Opportunity

Despite increasing competition, Celltrion has leapt into China's growing biosimilar market through a joint venture with Nan Fung, and another draw could lie in the biologics contract manufacturing potential in the country’s developing Greater Bay Area.

China Biosimilars

Oncology Dominates As China Drug, Biologic Approvals Surge

China saw a 150% increase in new drug approval applications in 2018, with oncology taking the lion's share of investigational new drug filings, notes a newly released annual report from China’s Center for Drug Evaluation. Meanwhile Darzalex has become the latest foreign drug to be approved.

China Approvals

Innovent And Lilly’s Rituximab Candidate Accepted By China’s NMPA

A new drug application for IBI301, a rituximab biosimilar candidate co-developed by Innovent and Eli Lilly, has been accepted by China’s NMPA.

Regulation Biosimilars

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival to similar bourses in the US and Hong Kong. But some are cautioning that local regulators and investors will need to step up if the so-called China Nasdaq is to gain traction.

China Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Innovent Biologics Inc.
  • Senior Management
  • Michael Yu, PhD, Pres. & CEO
    Ronald Ede, CFO
    Qinwei Zhou, PhD, COO
    Kerry L Blanchard, MD, PhD, CSO
  • Contact Info
  • Innovent Biologics Inc.
    Phone: 512 69566088
    168 Dongping St., Suzhou Industrial Park
    Suzhou, 215123
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register